v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Series A Warrants
Series C Warrants
March 2025 Pre Funded Warrants
March 2025 Common Warrants
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series A Warrants
Additional Paid-in Capital
Series C Warrants
Additional Paid-in Capital
March 2025 Pre Funded Warrants
Additional Paid-in Capital
March 2025 Common Warrants
Accumulated Deficit
Beginning balance at Dec. 31, 2024 $ (5,998)           $ 4 $ 1,233,797         $ (1,239,799)
Beginning balance (in shares) at Dec. 31, 2024             424,478            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 1,164             1,164          
Stock issued during period (in shares)             98,724            
Issuance of stock 2,222           $ 1 2,221          
Issuance of pre-funded warrants       $ 2,447 $ 4,174           $ 2,447 $ 4,174  
Net loss (10,616)                       (10,616)
Ending balance at Mar. 31, 2025 (6,607)           $ 5 1,243,803         (1,250,415)
Ending balance (in shares) at Mar. 31, 2025             523,202            
Beginning balance at Dec. 31, 2024 (5,998)           $ 4 1,233,797         (1,239,799)
Beginning balance (in shares) at Dec. 31, 2024             424,478            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (19,209)                        
Ending balance at Jun. 30, 2025 (13,986)           $ 5 1,245,017         (1,259,008)
Ending balance (in shares) at Jun. 30, 2025             535,509            
Beginning balance at Mar. 31, 2025 (6,607)           $ 5 1,243,803         (1,250,415)
Beginning balance (in shares) at Mar. 31, 2025             523,202            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 1,135             1,135          
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock units (in shares)             1,219            
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock units 77             77          
Cancellation of restricted stock awards (in shares)             (25)            
Exercise of prefunded warrants (in shares)             11,113            
Exercise of prefunded warrants 2             2          
Net loss (8,593)                       (8,593)
Ending balance at Jun. 30, 2025 $ (13,986)           $ 5 1,245,017         (1,259,008)
Ending balance (in shares) at Jun. 30, 2025             535,509            
Beginning balance (in shares) at Dec. 31, 2025 0         0              
Beginning balance at Dec. 31, 2025 $ 5,462         $ 0 $ 6 1,252,837         (1,247,381)
Beginning balance (in shares) at Dec. 31, 2025 646,537           646,537            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation $ 575             575          
Stock issued during period (in shares)           20,195              
Issuance of stock 0         $ 2,261              
Conversion of preferred stock to common stock and pre-funded warrants upon shareholder approval (in shares)           (20,195) (1,312,200)            
Conversion of convertible preferred stock to common stock and pre-funded warrants upon shareholder approval 2,261         $ (2,261) $ 13 2,248          
Reclassification of Common Warrants liability to equity   $ 16,705 $ 11,894           $ 16,705 $ 11,894      
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock units (in shares)             2,104            
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock units 1             1          
Exercise of prefunded warrants (in shares)             38,200            
Exercise of prefunded warrants 8           $ 1 7          
Net loss (24,199)                       (24,199)
Ending balance (in shares) at Mar. 31, 2026           0              
Ending balance at Mar. 31, 2026 $ 12,707         $ 0 $ 20 1,284,267         (1,271,580)
Ending balance (in shares) at Mar. 31, 2026             1,999,041            
Beginning balance (in shares) at Dec. 31, 2025 0         0              
Beginning balance at Dec. 31, 2025 $ 5,462         $ 0 $ 6 1,252,837         (1,247,381)
Beginning balance (in shares) at Dec. 31, 2025 646,537           646,537            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss $ (32,780)                        
Ending balance (in shares) at Jun. 30, 2026 0                        
Ending balance at Jun. 30, 2026 $ 4,695           $ 19 1,284,837         (1,280,161)
Ending balance (in shares) at Jun. 30, 2026 1,949,041           1,949,041            
Beginning balance (in shares) at Mar. 31, 2026           0              
Beginning balance at Mar. 31, 2026 $ 12,707         $ 0 $ 20 1,284,267         (1,271,580)
Beginning balance (in shares) at Mar. 31, 2026             1,999,041            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 569             569          
Issuance of pre-funded warrants in exchange for common stock (in shares)             (50,000)            
Issuance of pre-funded warrants in exchange for common stock 0           $ (1) 1          
Net loss $ (8,581)                       (8,581)
Ending balance (in shares) at Jun. 30, 2026 0                        
Ending balance at Jun. 30, 2026 $ 4,695           $ 19 $ 1,284,837         $ (1,280,161)
Ending balance (in shares) at Jun. 30, 2026 1,949,041           1,949,041